Preliminary Data on 225Ac-J591 Shows Promise in Treating mCRPC
At the 2020 Genitourinary Cancers Symposium, Scott T. Tagawa, MD, MS, shared promising preliminary data from a phase I dose-escalation trial (NCT03276572) involving 225Ac-J591 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The trial results showed that 63.6% of 22 men treated with 225Ac-J591 experienced some degree of prostate-specific antigen (PSA) decline, with 40.9% of men achieving a PSA decline of more than 50%.
Most participants had previously undergone treatment with lutetium-177 PSMA-617. According to Tagawa, the findings suggest that increasing the potency of an α emitter could potentially overcome resistance developed after treatment with a β emitter.
Looking ahead, combination strategies involving androgen receptor-targeted therapy, hormonal therapy, immune checkpoint inhibitors, and PARP inhibitors are expected to enhance treatment efficacy in mCRPC, as concluded by Tagawa.